Laboratoires Pierre Fabre : FDA-„Fast-Track"-Status für Elticertinib bei NSCLC ...Middle East

PR Newswire - News

CASTRES, Frankreich, 17. November 2026 /PRNewswire/ -- Laboratoires Pierre Fabre gibt bekannt, dass die U.S. Food and Drug Administration (FDA) Elticertinibi (auch bekannt als PFL-721, vormals STX-721) den „Fast-Track"-Status für die Behandlung erwachsener Patienten mit lokal...

    Hence then, the article about laboratoires pierre fabre fda fast track status fur elticertinib bei nsclc was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

    Read More Details
    Finally We wish PressBee provided you with enough information of ( Laboratoires Pierre Fabre : FDA-„Fast-Track"-Status für Elticertinib bei NSCLC )

    Apple Storegoogle play

    Last updated :

    Also on site :

    Most viewed in News